Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics (Nasdaq: TTRX) said its topical IL-36/IL-31 inhibitor GX-03 was named one of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online on Nov 11, 2025. The company said GX-03 is the first topical agent targeting IL-36 and demonstrated inhibition of IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn described GX-03 as a potential alternative to systemic and injectable therapies for eczema and psoriasis. The company also said it expects to announce topline data from its lead severe eczema program in early 2026.
Patient Care Online is described as a clinical news resource for office-based clinicians covering drug approvals, research commentary, and clinical trial highlights.
Turn Therapeutics (Nasdaq: TTRX) ha detto che il suo inibitore topico IL-36/IL-31 GX-03 è stato nominato una delle « Cinque meccanismi innovativi che stanno rimodellando il trattamento della dermatite atopica » da Patient Care Online il 11 novembre 2025. L'azienda ha detto che GX-03 è il primo agente topico mirato a IL-36 e ha dimostrato l'inibizione di IL-36 alpha, IL-31, IL-4 e IL-36 gamma. Turn ha descritto GX-03 come una potenziale alternativa alle terapie sistemiche e iniettabili per eczema e psoriasi. L'azienda ha anche detto che si aspetta di annunciare dati preliminari dal suo programma principale per eczema severo all'inizio del 2026.
Patient Care Online è descritto come una risorsa di notizie cliniche per medici di ambulatorio che copre approvazioni di farmaci, commenti di ricerca e punti salienti degli studi clinici.
Turn Therapeutics (Nasdaq: TTRX) dijo que su inhibidor tópico IL-36/IL-31 GX-03 fue nombrado una de “Cinco mecanismos novedosos que están dando forma al tratamiento de la dermatitis atópica” por Patient Care Online el 11 de noviembre de 2025. La empresa dijo que GX-03 es el primer agente tópico que apunta a IL-36 y demostró inhibición de IL-36 alfa, IL-31, IL-4 y IL-36 gamma. Turn describió GX-03 como una posible alternativa a terapias sistémicas e inyectables para eczema y psoriasis. La empresa también dijo que espera anunciar datos iniciales (topline data) de su programa líder para eczema severo a principios de 2026.
Patient Care Online se describe como un recurso de noticias clínicas para médicos en consultorios que cubre aprobaciones de fármacos, comentarios de investigación y aspectos destacados de ensayos clínicos.
Turn Therapeutics (Nasdaq: TTRX)은 국소 IL-36/IL-31 억제제 GX-03이 Patient Care Online에 의해 2025년 11월 11일에 아토피 피부염 치료를 재편하는 다섯 가지 새로운 메커니즘 중 하나로 선정되었다고 밝혔다. 회사는 GX-03이 IL-36를 표적하는 최초의 국소 제제이며 IL-36 알파, IL-31, IL-4 및 IL-36 감마를 억제하는 것을 입증했다고 말했다. Turn은 GX-03을 습진과 건선에 대한 전신 및 주사 치료에 대한 잠재적 대안으로 설명했다. 또한 이 회사는 주력 심한 습진 프로그램의 최종 데이터(topline data)를 2026년 초에 발표할 것으로 예상한다고 말했다.
Patient Care Online은 약물 승인, 연구 논평, 임상 시험 하이라이트를 다루는 임상 소식 리소스로 설명된다.
Turn Therapeutics (Nasdaq: TTRX) a déclaré que son inhibiteur topique IL-36/IL-31, GX-03, a été nommé l’un des « cinq mécanismes novateurs qui transforment le traitement de la dermatite atopique » par Patient Care Online le 11 novembre 2025. L’entreprise a indiqué que GX-03 est le premier agent topique ciblant IL-36 et a démontré l’inhibition de IL-36 alpha, IL-31, IL-4 et IL-36 gamma. Turn a décrit GX-03 comme une alternative potentielle aux thérapies systémiques et injectables pour l’eczéma et le psoriasis. L’entreprise a également dit qu’elle prévoit d’annoncer des données préliminaires (topline data) de son programme majeur pour l’eczéma sévère au début de 2026. Patient Care Online est décrit comme une ressource d’actualités cliniques pour les médecins en cabinet couvrant les autorisations de médicaments, les commentaires de recherche et les points forts des essais cliniques.
Turn Therapeutics (Nasdaq: TTRX) teilte mit, dass sein topisches IL-36/IL-31-Inhibitor GX-03 von Patient Care Online am 11. November 2025 zu den „Fünf neuartigen Mechanismen, die die Behandlung der atopischen Dermatitis neu gestalten“ gehört wurde. Das Unternehmen sagte, GX-03 sei das erste topische Mittel, das IL-36 adressiert, und zeige Hemmung von IL-36 Alpha, IL-31, IL-4 und IL-36 Gamma. Turn beschrieb GX-03 als potenzielle Alternative zu systemischen und injizierbaren Therapien für Ekzem und Psoriasis. Das Unternehmen sagte auch, dass es voraussichtlich im frühen 2026 die Topline-Daten aus seinem führenden Programm für schweres Ekzem bekannt geben werde. Patient Care Online wird beschrieben als eine klinische News-Ressource für Praxisärzte, die Medikamentenzulassungen, Forschungs-Kommentare und Highlights klinischer Studien abdeckt.
Turn Therapeutics (ناسداك: TTRX) قالت إن مثبِّط IL-36/IL-31 الموضعي GX-03 اختُير كإحدى “خمسة آليات جديدة تعيد تشكيل علاج التهاب الجلد التأتبي” من قبل Patient Care Online في 11 نوفمبر 2025. قالت الشركة إن GX-03 هو أول دواء موضعي يستهدف IL-36 وأظهر تثبيط IL-36 ألفا و IL-31 و IL-4 و IL-36 جاما. وصفت Turn GX-03 بأنه بديل محتمل للعلاجات الجهازية والتحاقنية لمرض الأكزيما والصدفية. كما قالت إن من المتوقع إعلان بيانات رئيسية (topline data) من برنامجها الرائد للأكزيما الشديدة في أوائل 2026. ويُوصف Patient Care Online بأنه مصدر أخبار إكلينيكية للأطباء في العيادات يغطي الاعتمادات الدوائية والتعليقات البحثية وتسليط الضوء على التجارب السريرية.
- Recognition: Named a top-five novel mechanism by Patient Care Online on Nov 11, 2025
- First topical IL-36 target: GX-03 described as the first topical agent addressing IL-36
- Preclinical/biologic activity: GX-03 reported to inhibit IL-36 alpha, IL-31, IL-4, and IL-36 gamma
- Near-term milestone: Topline data expected in early 2026
- Clinical-stage only: No approvals; GX-03 remains investigational
- Competition: Other Phase 2/3 candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar cited
Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine.
“We are honored to have our GX-03 technology be recognized as a top innovation by this widely read online magazine and this surprise designation further validates our goal of bringing best-in-class eczema products to patients in need,” said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. “IL-36 is implicated in the inflammatory cascade behind atopic dermatitis, eczema and psoriasis, and our technology, with its novel mechanism of action, represents the first topical agent to address this target, offering patients a potential alternative to systematics and injectables. Our studies have demonstrated GX-03’s ability to inhibit several key targets including IL-36 alpha, IL-31, as well as IL-4 and IL-36 gamma, all of which are linked to both eczema and psoriasis. We are working diligently to bring our proprietary pipeline of therapeutics to market and look forward to announcing topline data from our lead program in severe eczema in early 2026.”
Patient Care Online is a comprehensive educational and clinical news resource for office-based care clinicians of all backgrounds. Using a variety of media, Patient Care Online provides practical information across the range of disease states and conditions seen daily in frontline clinical practice. Clinicians come to Patient Care Online for news on drug approvals and commentary on the most current research, for video and podcast interviews with primary investigators and clinician thought leaders, for slide shows that provide at-a-glance highlights of clinical trials, professional society guidelines, and trending data, all developed with a focus on application to improve patient care.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The Company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.
Forward-Looking Statement
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company’s registration statement, the success of development programs, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.
Investor Relations:
Monique Kosse, Managing Director
Gilmartin Group
Investors@TurnTherapeutics.com
Media Contact:
media@TurnTherapeutics.com
FAQ
What did Turn Therapeutics (TTRX) announce about GX-03 on November 11, 2025?
When does Turn (TTRX) expect topline data for its lead severe eczema program?
How does Turn describe GX-03’s mechanism versus existing eczema treatments?
Is GX-03 approved for atopic dermatitis or psoriasis?
Which competitors were named alongside Turn’s GX-03 in the article?
What significance does Patient Care Online recognition have for Turn (TTRX)?
